Ireland
--:--IST
Recruiting Observational

Clinical Characteristics and Risk Factors of Children Suffering From Inflammatory Bowel Diseases At Assiut University Children Hospital

NCT05002166 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2021-08-05
Last updated
2021-08-12

Condition(s) studied

Inflammatory Bowel Disease

Investigational drug(s) / intervention(s)

labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.

labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.: labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.

Study summary

Clinical Characteristics and Risk factors of Children Suffering from Inflammatory Bowel Diseases At Assiut University Children Hospital

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: \- Children aged less than 18 years with a confirmed diagnosis of IBD. Exclusion Criteria: * Children with colitis other than IBD or children with systemic diseases affecting GIT.

Primary outcome measure(s)

  • Clinical characteristics and risk factors for IBD — 6 months
    To study the natural history, patterns, and clinical characteristics (as history of real bleeding, mucus or blood in the stool, diarrhea, abdominal pain ,vomiting)and risk factors of inflammatory bowel diseases (IBD) at Assiut University Children Hospital

Trial sites (1)

FacilityCityRegionStatus
Christine zaghloul noos Asyut Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05002166 on ClinicalTrials.gov ↗ ← All trials in Egypt